H. Lundbeck A/S Class A · OMXCOP:HLUN_A

H. Lundbeck A/S Class A — Lundbeck — 43rd Annual J.P. Morgan Healthcare Conference 2025

16 slides from H. Lundbeck A/S Class A's conference presentation, Jan 13, 2025

  1. Slide 1: Focused innovation driving sustainable growth

    Focused innovation driving sustainable growth The 43rd Annual J.P. Morgan Healthcare Conference – January 13, 2025 Martha Living with depression and ADHD

  2. Slide 2: Safe Harbor/Forward-Looking Statements

    Safe Harbor/Forward-Looking Statements This presentation This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward-looking statements include, without limit

  3. Slide 3: Creating value in growing neuroscience market

    Creating value in growing neuroscience market Well-positioned to secure future success Our Focused Innovator strategy Neuroscience market growth 8% CAGR expected 2022-20281 Growth Secure mid-term growth Neuroscience in top 3 for new drug approvals U.S. and EU2 Innovation Lead with focused innovation

  4. Slide 4: Leveraging our neuroscience knowledge and competences

    Leveraging our neuroscience knowledge and competences Eight out of nine pipeline programs are in neuro-specialty and neuro-rare Focused innovation Aiming for Our three selected strategic focus areas 4 assets in phase III in 2026 Well-positioned to launch >2 Grow Expand Build impactful our psychiatry

  5. Slide 5: Delivering on our Focused Innovator strategy

    Delivering on our Focused Innovator strategy Building pipeline for sustainable long-term growth Strong operational momentum Targeted commercial focus Strategic brands +21% in 9M 2024 Successful launch of Rexulti AADAD in the U.S. Growth Vyepti +76%, Brintellix/Trintellix +14%, Rexulti +16% Exception

  6. Slide 6: Strong growth driven by four strategic brands

    Growth Strong growth driven by four strategic brands Innovation Ambition to be leader in neuroscience underpinned by 75% revenue contribution of strategic brands Funding Current commercial value drivers1 Mid-term strategic growth ambition Mid-teen-digit CAGR into 2027 Rexulti with potential upside f

  7. Slide 7: Leveraging Vyepti and Rexulti growth opportunities

    Growth Leveraging Vyepti and Rexulti growth opportunities Innovation New geographical areas and indications provide potential for additional commercial expansion Funding SUNRISE study supports significant Successful AADAD launch drives potential in Asia following approval increased sales momentum ac

  8. Slide 8: Focused Innovator built on disciplined R&D investments

    Growth Focused Innovator built on disciplined R&D investments Innovation Strong competencies and new technologies combined with focused progression of innovative programs Funding Where we play Grow our psychiatry core Expand Breakthrough pipeline potential neuro-specialty position through rigorous d

  9. Slide 9: Transformed pipeline accelerating long-term growth

    Growth Transformed pipeline accelerating long-term growth Innovation Strong momentum with focus on new target biologies and drug modalities Funding Phase I Phase II Phase III 2020 onwards 2023-2024 2026 Rebuilding momentum Two first-in-class Aiming through innovative early development programs … +2

  10. Slide 10: Bexicaserin – A scientifically de-risked asset in phase III

    Growth Bexicaserin – A scientifically de-risked asset in phase III Innovation A late-stage asset in attractive neuro-rare space supporting long-term sustainable growth ambitions Funding Bexicaserin Backed by phase II clinical data • Broad potential across DEEs Mode of action • Differentiated molecul

  11. Slide 11: Amlenetug – First potential disease modifying therapy

    Growth Amlenetug – First potential disease modifying therapy Innovation Further strengthen our evolving neuro-rare franchise Funding Amlenetug Potential first-in-class antibody with strong technical profile • Binds all major forms of α-synuclein and prevents aggregation Mode of action • Clinical pro

  12. Slide 12: Pipeline as the foundation for future growth

    Growth Pipeline as the foundation for future growth Innovation Supported by science and innovation Funding Current commercial value drivers1 Future opportunities for expansion Bexicaserin Amlenetug DKK 3.8bn DKK 2.1bn USD ~1.5-2bn USD ~1.5-3bn +16% +76% Estimated peak sales2 Potential market size3 A

  13. Slide 13: Value-creating strategic capital reallocation

    Growth Value-creating strategic capital reallocation Innovation Delivering long-term sustainable growth in line with leading industry peers Funding Our transformation Significant capital reallocation program More than 30 • Supporting active pipeline build cross-functional workstreams are contributin

  14. Slide 14: A news-rich period ahead

    A news-rich period ahead Key events in pipeline progression Project Area Milestones Phase II OLE1 Bexicaserin (5-HT2C agonist) DEEs Read-out 12m Q1 2025 sNDA Brexpiprazole PTSD FDA Advisory Committee H1 2025 Phase Ib CAH Lu AG13909 (anti-ACTH mAb) Neuro-hormonal dysfunctions Read-out Q2 2025 Phase I

  15. Slide 15: Focused innovation driving long-term sustainable growth

    Focused innovation driving long-term sustainable growth Accelerating pipeline momentum combined with disciplined investment to secure future success Growth Innovation Funding • Vyepti and Rexulti • 8 out of 9 pipeline • Significant capital driving mid-term growth programs in neuro- reallocation prog

  16. Slide 16: JPM Annual Healthcare Conference 2025. © 2025 Lundbeck. All rights reserved.

    JPM Annual Healthcare Conference 2025. © 2025 Lundbeck. All rights reserved.

Lundbeck — 43rd Annual J.P. Morgan Healthcare Conference 2025 on 6ix